J Larsen1, B Hylleberg, K Ng, P Damsbo. 1. Clinical Development, Diabetes, and. Clinical Statistics, Novo Nordisk A/S, Bagsvaerd, Denmark. jenl@novonordisk.com
Abstract
OBJECTIVE: To assess the efficacy and safety of glucagon-like peptide-1 (GLP-1) on the plasma glucose level when given as a continuous infusion for either 16 or 24 h per day to type 2 diabetic patients who were poorly controlled on sulfonylurea treatment. RESEARCH DESIGN AND METHODS: This single-center, randomized, parallel, double-blind, placebo-controlled trial was conducted in 40 hospitalized patients who were randomized to receive infusions of either placebo or GLP-1 4 or 8 ng. kg(-1). min(-1) for either 16 or 24 h per day for 7 days. At predetermined intervals, 24-h profiles of glucose, glucagon, and insulin were measured. Adverse events and clinical chemistry and hematology were recorded. RESULTS: For all active treatment groups, the change in average glucose (area under the curve [AUC] for day 7 minus AUC for day 0 divided by 24 h) was statistically significantly different from placebo (P < or = 0.001). The GLP-1 8 ng. kg(-1). min(-1) dose given for 24 h was more efficacious than any of the other doses (P < or = 0.05). Nocturnal and fasting plasma glucose levels at day 7 were greater in the 16-h groups compared with the 24-h groups (P < or = 0.05). Insulin AUC did not show any treatment effect for any of the treatment groups when change was assessed from day 0 to day 7. However, for the 16-h groups, the pattern of the insulin profiles changed; the insulin profiles were considerably higher during the initial 3-4 h after restart of the GLP-1 infusion on day 7, although there was a tendency for insulin levels to decrease during the afternoon and evening. Glucagon AUC decreased significantly for all active treatment groups compared with placebo. GLP-1 was generally well tolerated. CONCLUSIONS: This study demonstrated that GLP-1 should be given continuously to obtain the most optimal glycemic control. Because of the short plasma half-life of native GLP-1, long-acting derivatives should be developed to make GLP-1 treatment clinically relevant.
RCT Entities:
OBJECTIVE: To assess the efficacy and safety of glucagon-like peptide-1 (GLP-1) on the plasma glucose level when given as a continuous infusion for either 16 or 24 h per day to type 2 diabeticpatients who were poorly controlled on sulfonylurea treatment. RESEARCH DESIGN AND METHODS: This single-center, randomized, parallel, double-blind, placebo-controlled trial was conducted in 40 hospitalized patients who were randomized to receive infusions of either placebo or GLP-1 4 or 8 ng. kg(-1). min(-1) for either 16 or 24 h per day for 7 days. At predetermined intervals, 24-h profiles of glucose, glucagon, and insulin were measured. Adverse events and clinical chemistry and hematology were recorded. RESULTS: For all active treatment groups, the change in average glucose (area under the curve [AUC] for day 7 minus AUC for day 0 divided by 24 h) was statistically significantly different from placebo (P < or = 0.001). The GLP-1 8 ng. kg(-1). min(-1) dose given for 24 h was more efficacious than any of the other doses (P < or = 0.05). Nocturnal and fasting plasma glucose levels at day 7 were greater in the 16-h groups compared with the 24-h groups (P < or = 0.05). Insulin AUC did not show any treatment effect for any of the treatment groups when change was assessed from day 0 to day 7. However, for the 16-h groups, the pattern of the insulin profiles changed; the insulin profiles were considerably higher during the initial 3-4 h after restart of the GLP-1 infusion on day 7, although there was a tendency for insulin levels to decrease during the afternoon and evening. Glucagon AUC decreased significantly for all active treatment groups compared with placebo. GLP-1 was generally well tolerated. CONCLUSIONS: This study demonstrated that GLP-1 should be given continuously to obtain the most optimal glycemic control. Because of the short plasma half-life of native GLP-1, long-acting derivatives should be developed to make GLP-1 treatment clinically relevant.
Authors: Lotte Bjerre Knudsen; Dan Kiel; Min Teng; Carsten Behrens; Dilip Bhumralkar; János T Kodra; Jens J Holst; Claus B Jeppesen; Michael D Johnson; Johannes Cornelis de Jong; Anker Steen Jorgensen; Tim Kercher; Jarek Kostrowicki; Peter Madsen; Preben H Olesen; Jacob S Petersen; Fritz Poulsen; Ulla G Sidelmann; Jeppe Sturis; Larry Truesdale; John May; Jesper Lau Journal: Proc Natl Acad Sci U S A Date: 2007-01-09 Impact factor: 11.205
Authors: Chuan-an Shen; Shawn Fagan; Alan J Fischman; Edward E Carter; Jia-Ke Chai; Xiao-Ming Lu; Yong-Ming Yu; Ronald G Tompkins Journal: Surgery Date: 2011-02-05 Impact factor: 3.982
Authors: A D Dobrian; Q Ma; J W Lindsay; K A Leone; K Ma; J Coben; E V Galkina; J L Nadler Journal: Am J Physiol Endocrinol Metab Date: 2010-11-16 Impact factor: 4.310
Authors: Lawrence Rosenberg; Mark Lipsett; Ji-Won Yoon; Marc Prentki; Rennian Wang; Hee-Sook Jun; Gary L Pittenger; David Taylor-Fishwick; Aaron I Vinik Journal: Ann Surg Date: 2004-11 Impact factor: 12.969
Authors: Jeppe Sturis; Carsten F Gotfredsen; John Rømer; Bidda Rolin; Ulla Ribel; Christian L Brand; Michael Wilken; Karsten Wassermann; Carolyn F Deacon; Richard D Carr; Lotte Bjerre Knudsen Journal: Br J Pharmacol Date: 2003-07-29 Impact factor: 8.739
Authors: Mary Courtney Moore; Ulrich Werner; Marta S Smith; Tiffany D Farmer; Alan D Cherrington Journal: Am J Physiol Endocrinol Metab Date: 2013-10-22 Impact factor: 4.310